Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

U.S. must address IP and market access barriers abroad to protect American innovation

By Ernest Kawka  |    January 31, 2023
PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...   Read More

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

By Reid Porter  |    January 31, 2023
Middlemen don’t want patients to know how they are stacking the deck against them.   Read More

New Report: More than 160 medicines in development for mental illness

By Matthew Norawong  |    January 26, 2023
Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder,...   Read More

ICYMI: Cancer death rate continues to decline due to treatment advances

By Matthew Norawong  |    January 25, 2023
Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...   Read More

Novel medicines approved in 2022 offer increased treatment options for patients

By Andrew Powaleny  |    January 23, 2023
2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...   Read More

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

By Katie Koziara  |    January 19, 2023
This January, PhRMA joined health care leaders, investors, R&D experts and members of the media at the 2023 J.P. Morgan Health Care Conference in San Francisco, CA. During this week, we discussed...   Read More

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

By Douglas Petersen  |    January 17, 2023
Last summer, the United States and Taiwan launched the U.S.-Taiwan Initiative on 21st-Century Trade to deepen economic and trade relations. In detailed comments to the U.S. Trade Representative...   Read More

WTAS: Inflation Reduction Act already impacting R&D decisions

By Nicole Longo  |    January 17, 2023
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...   Read More

Study finds hepatitis C cure saved Medicaid $15 billion

By Lindsey Seidlitz  |    January 5, 2023
New research published in the American Journal of Managed Care (AJMC) underscores the critical role that medicines play in improving health and reducing disease complications and other, often costly,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates